Skip to main content
. 2021 Jan 11;11:430. doi: 10.1038/s41598-020-79948-x

Figure 6.

Figure 6

PAI-1 inhibition triggers a lipid-lowering effect mediated by PCSK9 downregulation. As TM5614 inhibits PAI-1 activity, hepatic PCSK9 is downregulated at the transcriptional level (1). Consequently, plasma levels of PCSK9 decrease (2). Lower plasma PCSK9 levels exert a lower impact on catabolism of the LDL receptor (3), enabling the receptor to clear larger amounts of LDL-C from the circulation (4). The increase in intracellular cholesterol triggers the translocation of cholesterol sensing factors to the nucleus (5) to downregulate the transcription of genes involved in lipid metabolism (6). LRP-1, c-MET or FGFR/KlothoB are potential mediators for the observed effect. Animation created with https://biorender.com/.